Last Updated on January 3, 2025 by The Health Master
Indian Pharma
The Indian pharma sector has made remarkable strides in adhering to the stringent regulations of the US Food and Drug Administration (USFDA) in 2024.
Data reveals a significant decline in the number of adverse classification outcomes from USFDA inspections, a positive indicator of the industry’s growing commitment to global quality standards across biologics, drugs, and medical devices.
Declining Adverse Findings: A Sign of Progress
In 2023, the USFDA conducted 225 inspections, resulting in 18 cases of Official Action Indicated (OAI) and 117 cases of Voluntary Action Indicated (VAI).
Notably, in 2024, despite a tightening of regulatory scrutiny, the number of inspections decreased to 206, while OAI cases fell to 14 and VAI cases reduced to 115.
This trend signifies a growing alignment of the Indian pharma industry with global best practices for quality manufacturing.
Historical Perspective: Overcoming the Pandemic Impact
A review of pre-pandemic data reveals a significant increase in OAI status from 2018 to 2019. However, the onset of the COVID-19 pandemic in 2020 led to a substantial 75% drop in OAI cases.
This downward trend continued in 2021 with a further 50% reduction.
Understanding USFDA Inspection Classifications
- Voluntary Action Indicated (VAI): This classification indicates the presence of objectionable conditions or practices during an inspection. However, the facility is given the opportunity to voluntarily correct these issues without immediate regulatory action from the FDA.
- Official Action Indicated (OAI): This classification signifies serious regulatory violations that pose significant risks to safety, welfare, or data reliability. The FDA may recommend actions such as warning letters, untitled letters, or even legal action in such cases.
- No Action Indicated (NAI): This classification is assigned when no violations are found during an inspection.
The USFDA typically communicates the final inspection classification to the firm within 45 to 90 days following the completion of the inspection.
Key Factors Contributing to the Improvement
The Indian Pharmaceutical Alliance (IPA) attributes this significant improvement to a multi-pronged approach:
- Prioritizing Quality Culture: Senior leadership in Indian pharma companies has placed a strong emphasis on fostering a quality-centric culture.
- Operational Enhancements:
- Automation: Advanced automation technologies have been implemented in manufacturing plants to enhance precision, efficiency, and reduce human error.
- Robust SOPs: Comprehensive Standard Operating Procedures (SOPs) have been established and rigorously followed to ensure consistency and minimize deviations.
- Employee Training and Development: Accelerated employee training programs have been implemented to enhance skills, align with global standards, and build a highly competent workforce.
IPA Emphasizes Continued Commitment to Quality
IPA Secretary General Sudarshan Jain emphasized the industry’s unwavering commitment to continuous improvement in quality standards.
“This progress underscores our dedication to advancing quality standards in India. We view this as an ongoing endeavor to strengthen the quality culture and ensure alignment with global benchmarks,” Jain stated.
-
What is the significance of USFDA compliance for Indian pharma companies?
USFDA compliance is crucial for Indian pharma companies to gain access to the lucrative US market and maintain global competitiveness.
-
What are the key steps taken by Indian pharma companies to improve USFDA compliance?
Key steps include fostering a quality-centric culture, implementing advanced automation, establishing robust SOPs, and providing comprehensive employee training.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This article is for informational purposes only and should not be considered financial or legal advice.
USFDA proposes stricter testing for Asbestos in Talcum Powder Cosmetics
USFDA issues EIR to Aarti Drugs for Tarapur facility
USFDA issues VAI status to Biocon for Bengaluru API facility
USFDA issued Form 483 with two observations to Aurobindo for API plant
FSSAI: Food Labelling and Display – Chapter-13
Key Notes on Revised Schedule M: Point No. 17 – Documentation
Homoeopathic Doctors can Practice in Allopathy: FDA Maharashtra
Spurious drugs: Low conviction rate a concern
Drug alert: 111 drug samples declared as NSQ in November 2024
Key Notes on Revised Schedule M: Point No. 16 – Waste materials
USFDA proposes stricter testing for Asbestos in Talcum Powder Cosmetics
Spurious Drug: New Rules for Medical Stores soon
CM Haryana assures full support for Karnal Pharma Park
Key Notes on Revised Schedule M: Point No. 15 – Reference Standards
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
